Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2025)

Crinetics Pharmaceuticals has reported Enterprise Value over the past 9 years, most recently at -$1.0 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$1.0 billion for Q4 2025, up 24.09% from a year ago — trailing twelve months through Dec 2025 was -$1.0 billion (up 24.09% YoY), and the annual figure for FY2025 was -$1.0 billion, up 24.09%.
  • Enterprise Value for Q4 2025 was -$1.0 billion at Crinetics Pharmaceuticals, up from -$1.1 billion in the prior quarter.
  • Over the last five years, Enterprise Value for CRNX hit a ceiling of -$34.6 million in Q4 2022 and a floor of -$1.4 billion in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$351.3 million (2021), compared with a mean of -$552.4 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 89.63% in 2022 and later crashed 2052.27% in 2024.
  • Crinetics Pharmaceuticals' Enterprise Value stood at -$334.2 million in 2021, then skyrocketed by 89.63% to -$34.6 million in 2022, then tumbled by 1512.41% to -$558.6 million in 2023, then tumbled by 142.42% to -$1.4 billion in 2024, then rose by 24.09% to -$1.0 billion in 2025.
  • The last three reported values for Enterprise Value were -$1.0 billion (Q4 2025), -$1.1 billion (Q3 2025), and -$1.2 billion (Q2 2025) per Business Quant data.